OncLiveGenmab Focuses Oncology Research on Monoclonal AntibodiesOncLiveTony Berberabe, MPH. Published Online: Thursday, February 6, 2014. Genmab, the publicly traded, international biotechnology company, has an oncology pipeline that focuses on two cla…
|
AbbVie Inc. Is Closer to Much-Needed Diversification, but Is It Enough?
DailyFinance Other drugs like Elagolix and daclizumab also address meaningful potential markets, and AbbVie isn’t known for moving low-probability drugs into expensive late-stage tests. Even so, there are “buts” here – the success of Elagolix and daclizumab will … |
|
AbbVie Inc. Is Closer to Much-Needed Diversification, but Is It Enough?
Motley Fool Other drugs like Elagolix and daclizumab also address meaningful potential markets, and AbbVie isn’t known for moving low-probability drugs into expensive late-stage tests. Even so, there are “buts” here – the success of Elagolix and daclizumab will … |
Roach: Devic disease is autoimmune attack on optic nerveAlexandria Town TalkAntibodies show up in her bloodwork. She is about to undergo two treatments, two weeks apart, of rituximab, hopefully killing the antibodies. What little information I have fou…
Devic disease is autoimmune attack on optic nerveThe Detroit NewsAntibodies show up in her blood work. She is about to undergo two treatments, two weeks apart, of rituximab, hopefully killing the antibodies. What little information I have found online …
To your good health: Devic disease is autoimmune attack on optic nerveSt. Augustine RecordAntibodies show up in her bloodwork. She is about to undergo two treatments, two weeks apart, of rituximab, hopefully killing the antibodies. What little informat…
antibodies-online.com Supports the Resource Identification Initiative With …Sacramento BeeResearch resources reported in the biomedical literature often lack sufficient detail to be uniquely identified, which can hinder scientific reproducibility. To…
Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial ResultsBusiness Wire (press release)The recommendation followed a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progressio…
MedscapeIdelalisib Combo Rings Bells in Relapsed CLLMedscapeThat drug is idelalisib, a PI3 kinase delta isoform-specific inhibitor. The study by Furman and colleagues was a randomized, placebo-controlled, double-blind trial of rituximab plus placebo vs…
Financial ExpressNIH Scientists Find Mechanism That Helps HIV Evade Antibodies, Stabilize Key …RedOrbitNIH scientists have discovered a mechanism involved in stabilizing key HIV proteins and thereby concealing sites where some of the most powerful HI…